A public choice framework for controlling transmissible and evolving diseases

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue SUPPL. 1, 2010, Pages 1696-1701

  Althouse, Benjamin M ^a   Bergstrom, Theodore C ^b   Bergstrom, Carl T ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibiotic resistance; Emerging infectious disease; Externalities; Pandemic influenza; Vaccination

Indexed keywords

ANTIBIOTIC AGENT; OSELTAMIVIR; TETANUS TOXOID; ZANAMIVIR;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CLOSTRIDIUM TETANI; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DISEASE CONTROL; DISEASE PREDISPOSITION; DISEASE TRANSMISSION; DRUG EFFICACY; HAEMOPHILUS INFLUENZAE; HERD IMMUNITY; HUMAN; INCIDENCE; INFLUENZA VIRUS A H1N1; LIFESPAN; MEASLES; MEASLES VACCINATION; MORTALITY; MUSCLE CONTRACTION; NONHUMAN; OTITIS MEDIA; PANDEMIC; PARAMYXOVIRUS; PRIORITY JOURNAL; RISK ASSESSMENT; STREPTOCOCCUS PNEUMONIAE; TETANUS; TREATMENT FAILURE; VIRUS VIRULENCE; ECONOMICS; EPIDEMIC; INFECTION CONTROL; INFLUENZA; REVIEW; STATISTICAL MODEL; THEORETICAL MODEL;

COMMUNICABLE DISEASE CONTROL; DISEASE OUTBREAKS; HUMANS; INFLUENZA, HUMAN; MEASLES; MODELS, ECONOMETRIC; MODELS, THEORETICAL; OTITIS MEDIA; TETANUS;

EID: 76549098614     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0906078107     Document Type: Article

References (39)

1. Brito DL, Sheshinski E, Intriligator MD (1991) Externalities and compulsory vaccinations. J Public Econ 45:69-90.
2. Geoffard P-Y, Philipson T (1997) Disease eradication: Private versus public vaccination. Am Econ Rev 87:222-230.
3. Francis PJ (1997) Dynamic epidemiology and the market for vaccinations. J Public Econ 63:383-406.
4. Gersovitz M, Hammer JS (2003) Infectious diseases, public policy, and the marriage of economics and epidemiology. World Bank Res Obs 18:129-157.
5. Gersovitz M, Hammer JS (2004) The economic control of infectious diseases. Econ J 114:1-27.
6. Gersovitz M, Hammer JS (2004) Tax/subsidy policies toward vector-borne infectious diseases. J Public Econ 89:647-674.
7. Cook J, et al. (2009) Using private demand studies to calculate socially optimal vaccine subsidies in developing countries. J Policy Anal Manage 28:6-28.
8. Bauch CT, Galvani AP, Earn DJD (2003) Group interest versus self-interest in smallpox vaccination policy. Proc Natl Acad Sci USA 100:10564-10567.
9. Bauch CT, Earn DJD (2004) Vaccination and the theory of games. Proc Natl Acad Sci USA 101:13391-13394.
10. Reluga TC, Bauch CT, Galvani AP (2006) Evolving public perceptions and stability in vaccine uptake. Math Biosci 204:185-198.
11. Galvani AP, Reluga TC, Chapman GB (2007) Long-standing influenza vaccination policy is in accord with individual self-interest but not with the utilitarian optimum. Proc Natl Acad Sci USA 104:5692-5697.
12. Vardavas R, Breban R, Blower S (2007) Can influenza epidemics be prevented by voluntary vaccination? PLoS Comput Biol 3:e85.
13. van Boven M, Klinkenberg D, Pen I, Weissing FJ, Heesterbeek H (2008) Self-interest versus group-interest in antiviral control. PLoS One 3:e1558.
14. Medlock J, Galvani AP (2009) Optimizing influenza vaccine distribution. Science 325: 1705-1708.
15. Smith DL, Levin SA, Laxminarayan R (2005) Strategic interactions in multi-institutional epidemics of antibiotic resistance. Proc Natl Acad Sci USA 102:3153-3158.
16. Foster KR, Grundmann H (2006) Do we need to put society first? The potential for tragedy in antimicrobial resistance. PLoS Med 3:e29.
17. Fine PEM, Clarkson JA (1986) Individual versus public priorities in the determination of optimal vaccination policies. Am J Epidemiol 124:1012-1020.
18. Samuelson PA (1954) The pure theory of public expenditure. Rev Econ Stat 36: 387-389.
19. Samuelson PA (1955) Diagrammatic exposition of a theory of public expenditure. Rev Econ Stat 37:350-356.
20. Centers for Disease Control (2008) Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book) (Public Health Foundation, Washington, DC), 10th Ed.
21. Centers for Disease Control (1991) Diphtheria, tetanus, and pertussis: Recommendations for vaccine use and other preventive measures: Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep 40(RR-10):1-28.
22. Read AF, Mackinnon MJ (2008) Pathogen evolution in a vaccinated world. Evolution in Health and Disease, eds Stearns SC, Koella JC (Oxford University Press, Oxford), 2nd Ed.
23. World Health Organization (2007) Measles Fact Sheet (World Health Organization, Geneva).
24. Keeling MJ, Rohani P (2008) Modeling Infectious Diseases in Humans and Animals (Princeton University Press, Princeton, NJ).
25. Philipson T (1996) Private vaccination and public health: An empirical examination for U.S. measles. J Hum Resour 31:611-630.
26. McCaig LF, Besser RE, Hughes JM (2002) Trends in antimicrobial prescribing rates for children and adolescents. JAMA 287:3096-3102.
27. Goossens H, Ferech M, Vander Stichele R, Elseviers M; ESAC Project Group (2005) Outpatient antibiotic use in Europe and association with resistance: A cross-national database study. Lancet 365:579-587.
28. Lipsitch M (2001) Measuring and interpreting associations between antibiotic use and penicillin resistance in Streptococcus pneumoniae. Clin Infect Dis 32:1044-1054.
29. Lipsitch M, Samore MH (2002) Antimicrobial use and antimicrobial resistance: A population perspective. Emerg Infect Dis 8:347-354.
30. American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media (2004) Diagnosis and management of acute otitis media. Pediatrics 113:1451-1465.
31. Bergstrom CT, Feldgarden M (2008) The ecology and evolution of antibiotic-resistant bacteria. Evolution in Health and Disease, eds Stearns SC, Koella JC (Oxford University Press, Oxford), 2nd Ed.
32. Bonhoeffer S, Lipsitch M, Levin BR (1997) Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci USA 94:12106-12111.
33. Centers for Disease Control (2009) Interim Guidance on Antiviral Recommendations for Patients with Novel Influenza A (H1N1) Virus Infection and Their Close Contacts (Centers Dis Control, Atlanta).
34. World Health Organization (2006) WHO Rapid Advice Guidelines on Pharmacological Management of Humans Infected with Avian Influenza A (H5N1) Virus (World Health Organization, Geneva).
35. Centers for Disease Control (2009) Interim Recommendations for the Use of Influenza Antiviral Medications in the Setting of Oseltamivir Resistance Among Circulating Influenza A (H1N1) Viruses, 2008-09 Influenza Season (Centers Dis Control, Atlanta).
36. Weinstock DM, Zuccotti G (2009) The evolution of influenza resistance and treatment. JAMA 301:1066-1069.
37. Lipsitch M, Cohen T, Murray M, Levin BR (2007) Antiviral resistance and the control of pandemic influenza. PLoS Med 4:e15.
38. Handel A, Longini IM (2007) Jr, Antia R (2007) What is the best control strategy for multiple infectious disease outbreaks? Proc Biol Sci 274:833-837.
39. Traynor K (2008) Antiinfluenza medication kits need work, FDA advisers conclude. Am J Health Syst Pharm 65:2314-2316.